Type 2 diabetes in prepubertal children.


Journal

Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345

Informations de publication

Date de publication:
11 2021
Historique:
received: 20 07 2021
accepted: 28 07 2021
pubmed: 8 8 2021
medline: 4 2 2022
entrez: 7 8 2021
Statut: ppublish

Résumé

Puberty-induced insulin resistance is considered critical in the pathogenesis of type 2 diabetes (T2D) in youth. The development of T2D before puberty suggests distinct risk factors and pathophysiology but, because of its rarity, this has not been well studied. We aimed to describe the clinical characteristics of children with T2D diagnosed before the onset of puberty. We retrospectively studied all children with autoantibody-negative T2D and available pubertal development assessment seen at our center between July 2016 and July 2019, and compared characteristics of those at Tanner stage I (prepubertal, n = 35) versus those at Tanner II-V of pubertal development (n = 341). At T2D diagnosis, prepubertal children compared with those at Tanner II-V had higher body mass index z-score (p = 0.003) and higher C-peptide (p = 0.003) (while glucose levels were not significantly different), with differences retaining significance after adjustment for glucose, race/ethnicity and sex. Dyslipidemia occurred in 100% of prepubertal children versus 89.7% of those diagnosed later (p = 0.036). Of the prepubertal children diagnosed under age 10 (n = 13), 69.2% were female, 100% racial/ethnic minority, 100% had obesity with history of dyslipidemia and none with diabetic ketoacidosis. T2D, although rarely, can develop before puberty. Children with T2D diagnosed in the prepubertal period have more severe obesity, greater insulin resistance, and more frequent dyslipidemia than older youth. These findings suggest that children with prepubertal T2D are at increased risk for associated morbidity compared with older youth and underscore the significance of interventions to prevent and treat obesity in early childhood.

Identifiants

pubmed: 34363430
doi: 10.1111/pedi.13254
doi:

Substances chimiques

Autoantibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

946-950

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Dabelea D. Diabetes in youth looking backwards to inform the future: Kelly west award lecture 2017. Diabetes Care. 2018;41(2):233-240. https://doi.org/10.2337/dci17-0031
Liese AD. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for diabetes in youth study: SEARCH for diabetes in youth study group. Pediatrics. 2006;118(4):1510-1518. https://doi.org/10.1542/peds.2006-0690
Tryggestad JB, Willi SM. Complications and comorbidities of T2DM in adolescents: findings from the TODAY clinical trial. J Diabetes Complications. 2015;29(2):307-312. https://doi.org/10.1016/j.jdiacomp.2014.10.009
Bacha F, Gungor N, Lee S, Arslanian SA. Progressive deterioration of β-cell function in obese youth with type 2 diabetes. Pediatr Diabetes. 2013;14(2):106-111. https://doi.org/10.1111/j.1399-5448.2012.00915.x
Nadeau KJ, Hannon TS, Edelstein SL, et al. Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care. 2018;41(8):1717-1725. https://doi.org/10.2337/dc18-0787
Arslanian S, Pyle L, Payan M, et al. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and -βcell function in TODAY. Diabetes Care. 2013;36(6):1749-1757. https://doi.org/10.2337/dc12-2393
Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013;36(12):3863-3869. https://doi.org/10.2337/dc12-2455
Maahs DM, Snively BM, Bell RA, et al. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for diabetes in youth study. Diabetes Care. 2007;30(10):2593-2598. https://doi.org/10.2337/dc07-0450
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG. Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med. 2016 Nov;33(11):1554-1558. https://doi.org/10.1111/dme.13142
Foteinopoulou E, Clarke CAL, Pattenden RJ, et al. Impact of routine clinic measurement of serum C-peptide in people with a clinician-diagnosis of type 1 diabetes. Diabet Med. 2020;38(7):e14449. https://doi.org/10.1111/dme.14449
Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American diabetes association. Diabetes Care. 2018;41(12):2648-2668. https://doi.org/10.2337/dci18-0052
Mayer-Davis EJ, Kahkoska AR, Jefferies C, et al. ISPAD clinical practice consensus guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2018;19:7-19. https://doi.org/10.1111/pedi.12773
Pettitt DJ, Talton J, Dabelea D, et al. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. Diabetes Care. 2014;37(2):402-408. https://doi.org/10.2337/dc13-1838
Hutchins J, Barajas RA, Hale D, Escaname E, Lynch J. Type 2 diabetes in a 5-year-old and single center experience of type 2 diabetes in youth under 10. Pediatr Diabetes. 2017;18(7):674-677. https://doi.org/10.1111/pedi.12463
Klingensmith GJ, Connor CG, Ruedy KJ, et al. Presentation of youth with type 2 diabetes in the pediatric diabetes consortium. Pediatr Diabetes. 2016;17(4):266-273. https://doi.org/10.1111/pedi.12281
Eissa MA, Mihalopoulos NL, Holubkov R, Dai S, Labarthe DR. Changes in fasting lipids during puberty. J Pediatr. 2016;170:199-205. https://doi.org/10.1016/j.jpeds.2015.11.018
Tell GS, Mittelmark MB, Vellar OD. Cholesterol, high density lipoprotein cholesterol and triglycerides during puberty: the Oslo youth study. Am J Epidemiol. 1985;122(5):750-761. https://doi.org/10.1093/oxfordjournals.aje.a114158

Auteurs

Marcela Astudillo (M)

Diabetes and Endocrinology Section, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Mustafa Tosur (M)

Diabetes and Endocrinology Section, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Beatriz Castillo (B)

School of Medicine, Baylor College of Medicine, Houston, Texas, USA.

Ahmad Rafaey (A)

College of Natural Sciences and Mathematics, University of Houston, Houston, Texas, USA.

Alejandro F Siller (AF)

Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Jacobo Nieto (J)

Undergraduate School, Rice University, Houston, Texas, USA.

Stephanie Sisley (S)

Diabetes and Endocrinology Section, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
Children's Nutrition Research Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Siripoom McKay (S)

Diabetes and Endocrinology Section, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Aikaterini A Nella (AA)

Diabetes and Endocrinology Section, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Ashok Balasubramanyam (A)

Division of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine, Houston, Texas, USA.

Fida Bacha (F)

Children's Nutrition Research Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Maria J Redondo (MJ)

Diabetes and Endocrinology Section, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH